Life Sciences
and Health Care

We advised MorphoSys, a Germany-based biopharmaceutical company, on a global collaboration and license… Read more

We advised MorphoSys, a Germany-based biopharmaceutical company, on a global collaboration and license agreement with Incyte Corporation, a U.S. pharmaceutical company, to further develop and commercialize MorphoSys’ key asset tafasitamab, an anti-CD19 antibody currently in development to treat blood cancer.

Under the agreement, which is considered one of the largest licensing transactions of any German biotech company, MorphoSys will be eligible to receive milestone payments of up to US$1.1 billion and significant royalties.

Our Munich and Hamburg offices led the transaction, supported by our Los Angeles, Northern Virginia, and Washington, D.C. offices and our antitrust and intellectual property practices.

We advised Novartis, a leading global medicines company, on its acquisition of Vedere Bio… Read more

We advised Novartis, a leading global medicines company, on its acquisition of Vedere Bio, adding a powerful new platform for AAV-based delivery of gene therapies and a best-in-class optogenetics program to help reimagine the treatment and prevention of vision loss and blindness.

The acquisition builds on Novartis’ commitment in cell and gene therapy, and will enable Novartis to further advance its efforts to bring transformative therapies to a wide range of patients with blinding diseases.

A New York team led the transaction, with support from our Denver, Los Angeles, and Washington, D.C. offices and our employee benefits, employment, and tax practices.

We advised PerkinElmer, Inc., a global leader in the life sciences and diagnostics industry, on its public takeover… Read more

We advised PerkinElmer, Inc., a global leader in the life sciences and diagnostics industry, on its public takeover offer for Horizon Discovery Group PLC., a leading gene editing company.

With this investment, PerkinElmer will expand its portfolio of leading, automated life sciences discovery and applied genomics solutions to include CRISPR gene editing and gene modulation tools – important for the future of precision medicine.

A team of lawyers in our London office led the transaction, with support from our Birmingham, New York, Perth, and Washington, D.C. offices and our antitrust, employment, pensions, privacy and cybersecurity, private equity, and tax practices.

We advised Rexahn Pharmaceuticals, Inc., a biotechnology company, on its reverse merger... Read more

We advised Rexahn Pharmaceuticals, Inc., a biotechnology company, on its reverse merger transaction with Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company.

The transaction provided Rexahn’s stockholders with the opportunity to participate in a dynamic company with a robust pipeline in the growing ophthalmic market.

Lawyers in our Baltimore office led the transaction, with support from our Boston, Los Angeles, Philadelphia, Silicon Valley, and Washington, D.C. offices and our employee benefits, intellectual property, litigation, regulatory, securities and public company advisory, and tax practices.

Life Sciences and Health Care

“Accessible, reliable, great commitment to the client. Exceptionally good legal knowledge. Highly professional negotiating skills.”

Legal 500 Germany, 2020

500+

Life Sciences
and Health Care lawyers

Band 1

Life Sciences and Healthcare
Chambers Global, 2021

Sector performance

After a pause in deal activity because of the COVID-19 pandemic at the start of 2020, M&A in the life sciences and health care sector rebounded during the second half of the year. Deal activity trended toward a greater volume of smaller bolt-on acquisitions and partnering deals in lieu of the mega deals executed in preceding years.

Financing for life sciences and health care companies was strong across the board, from venture capital to IPOs and follow-on offerings. In addition, many of the drivers for transacting – access to new products and technologies, rationalizing and filling revenue gaps across products lines, and venture or PE-backed companies looking for an exit – remained in play.

Hogan Lovells activities

Our global Life Sciences and Health Care industry sector continues to regularly release guidance, webinars, and podcasts addressing the pandemic’s impact on the sector, which we catalog in our COVID-19 Resource Guide.

We released our annual Hogan Lovells LS&HC Horizons publicationproviding high-level insights into opportunities and challenges in the sector, along with our Talking the Cure podcast series, which seeks to foresee the industry issues facing our clients. Our Global Digital Health Team launched Virtual Health Horizons to explore the opportunities and potential legalhurdles in telehealth and remote monitoring.

Diversity and Inclusion

Diversity
and Inclusion

Pro Bono

Pro Bono

Our new Corporate & Finance partners and counsel

Our new
Corporate & Finance
partners and counsel

Our M&A  publications

Our M&A
publications

Technical excellence

Technical excellence

Executing transactions effectively

Industry knowledge

Industry knowledge

Understanding issues
in regulated industries

Global reach

Global reach

Worldwide reach,
local experience

Full-service capabilities

Full-service capabilities

Subject matter
knowledge

M&A Year in Review | 2020

This site uses cookies, if you continue without changing your settings, we'll assume that you are happy to receive all cookies. Click here to learn more about cookies.

Continue